Biotts creates a world without needles and pills. Company with another funding and award
Wroclaw-based Biotts is a Polish biopharmaceutical company, developing drug formulations and formulations, as well as proprietary carriers that increase the bioavailability of active substances. The innovative technology of the Wroclaw-based startup makes it possible to administer pharmaceutical preparations through the skin – thus facilitating the fight against many common and serious diseases whose treatment is still burdensome.
“Our goal was to create a technology that increases the bioavailability of drugs while weakening their side effects. Our versatile MTC-Y (Multifunctional Transdermal Carrier-Y) acts directly on pathologically altered tissues, guaranteeing a stronger therapeutic effect while reducing side effects. With the help of the system, it is possible to carry a number of new active substances, including up to 20 times more than those able to penetrate the skin using the technology available today. With this technology, we will reduce the cost of treatment and increase the comfort of life for millions of people by bringing our solutions widely to the market.”
– emphasizes Dr. Pawel Biernat, CEO of Biotts.
More Biotts milestones
The company has just received further support for the development of its technology – the “Lower Silesia Innovation Voucher”, in the amount of more than PLN 134,000. The grant, which is awarded to companies in Lower Silesia, finances research services, consultations with scientific units and a technology audit. What’s more, the project also funds research and development work on the implementation or development of a product and technology.
“We will use the grant to analyze the molecular structure of our transdermal carrier. The subject of the study carried out by the University of Opole will be the specialized analysis of the substances included in the patented carrier used to prepare a transdermal form of the drug based on hydrophilic substances of natural origin used in the treatment of diabetic foot, ulcers and skin cancer, among others. To date, there is no such form of the drug in both domestic and global medicine.”
– explains Dr. Jan Meler, co-founder of the company and a drug formulation technologist.
New therapies for diabetics an opportunity for millions of patients
This is not the end of the company’s successes. During the 5th Forum of Modern Diabetology in Poznan, a competition was held for the most innovative project supporting the treatment and self-control of patients with diabetes. The award for the most innovative project went to Biotts for its MTC-Y transdermal system. Evaluation of the competition projects was carried out by the Competition Committee chaired by Adrian Szulczynski. Winning is a cash prize and free registration to ATTD 2023 in Berlin!
“The Modern Technology Zone is already a tradition of the Modern Diabetology Forum. After the time of the pandemic, we returned to the Zone and to the startup project competition. We want to promote innovation so that every doctor and member of the therapeutic team not only knows about the existence of various modern solutions, but can test them, evaluate them, and then apply them to the patient. Thanks to the competition, more entities were able to present their innovative projects to support the treatment and self-control of patients with diabetes. This year’s winner was BIOTTS’ project – a Transdermal System that allows the administration of drugs with a peptide structure, i.e. GLP-1 analogs. By sticking the patch, the system allows the drug to be released in a very stable manner. Congratulations to the winning company BIOTTS!”
– said Adrian Szulczynski, Chairman of the Competition Committee, member of the Organizing Committee of the 5th Forum of Modern Diabetology.
“There is no such solution either in Poland or in the world – no one in the industry has heard of a technology that effectively penetrates the layers of the skin with active substances that are soluble not only in fat, but also in water. The gold standard in diabetes therapies includes pills, which burden the digestive system, and uncomfortable injections. No one before us has developed diabetes drugs administered through the skin. We have the technology that will change the world.”
– says Konrad Krajewski, vice president of Biotts.
Transdermal systems are growing in popularity
The market in which Biotts operates has been going from strength to strength for more than a dozen years, but – thanks to new technologies – still has the best ahead of it. According to research by Verified Market Research®, the global market for transdermal drug delivery systems was valued at $5.9 billion in 2020 and is expected to reach $8.4 billion by 2028, growing at a CAGR of 4.5% between 2021 and 2028.
